147 related articles for article (PubMed ID: 31962201)
1. Combined SRPK and AKT pharmacological inhibition is synergistic in T-cell acute lymphoblastic leukemia cells.
Siqueira RP; Caetano MMM; de Souza LÂ; Dos Passos PMS; Simaroli NB; Barros MVA; de Souza APM; de Oliveira LL; Silva-Júnior A; Fietto JLR; Teixeira RR; Teixeira FR; Bressan GC
Toxicol In Vitro; 2020 Jun; 65():104777. PubMed ID: 31962201
[TBL] [Abstract][Full Text] [Related]
2. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
[TBL] [Abstract][Full Text] [Related]
3. Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340).
Siqueira RP; Barbosa Éde A; Polêto MD; Righetto GL; Seraphim TV; Salgado RL; Ferreira JG; Barros MV; de Oliveira LL; Laranjeira AB; Almeida MR; Júnior AS; Fietto JL; Kobarg J; de Oliveira EB; Teixeira RR; Borges JC; Yunes JA; Bressan GC
PLoS One; 2015; 10(8):e0134882. PubMed ID: 26244849
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
[TBL] [Abstract][Full Text] [Related]
5. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
6. A copper chelate induces apoptosis and overcomes multidrug resistance in T-cell acute lymphoblastic leukemia through redox imbalance and inhibition of EGFR/PI3K/Akt expression.
Banerjee K; Das S; Sarkar A; Chatterjee M; Biswas J; Choudhuri SK
Biomed Pharmacother; 2016 Dec; 84():71-92. PubMed ID: 27639544
[TBL] [Abstract][Full Text] [Related]
7. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
8. Andrographolide inhibits growth of human T-cell acute lymphoblastic leukemia Jurkat cells by downregulation of PI3K/AKT and upregulation of p38 MAPK pathways.
Yang T; Yao S; Zhang X; Guo Y
Drug Des Devel Ther; 2016; 10():1389-97. PubMed ID: 27114702
[TBL] [Abstract][Full Text] [Related]
9. Antimetastatic effect of the pharmacological inhibition of serine/arginine-rich protein kinases (SRPK) in murine melanoma.
Moreira GA; Lima GDA; Siqueira RP; Barros MVA; Adjanohoun ALM; Santos VC; Barbosa ÉAA; Loterio RK; Paiva JC; Gonçalves VHS; Viol LCS; Marques-da-Silva EA; Júnior AS; Almeida MR; Fietto JLR; Machado-Neves M; Ferreira RS; Teixeira RR; Bressan GC
Toxicol Appl Pharmacol; 2018 Oct; 356():214-223. PubMed ID: 30138656
[TBL] [Abstract][Full Text] [Related]
10. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.
Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X
Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of hedgehog signaling by GANT58 induces apoptosis and shows synergistic antitumor activity with AKT inhibitor in acute T cell leukemia cells.
Hou X; Chen X; Zhang P; Fan Y; Ma A; Pang T; Song Z; Jin Y; Hao W; Liu F; Wang W; Wang Y
Biochimie; 2014 Jun; 101():50-9. PubMed ID: 24394624
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
13. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.
Simioni C; Neri LM; Tabellini G; Ricci F; Bressanin D; Chiarini F; Evangelisti C; Cani A; Tazzari PL; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Capitani S; Martelli AM
Leukemia; 2012 Nov; 26(11):2336-42. PubMed ID: 22614243
[TBL] [Abstract][Full Text] [Related]
15. Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs).
Siqueira RP; Barros MVA; Barbosa ÉAA; Onofre TS; Gonçalves VHS; Pereira HS; Silva Júnior A; de Oliveira LL; Almeida MR; Fietto JLR; Teixeira RR; Bressan GC
Eur J Med Chem; 2017 Jul; 134():97-109. PubMed ID: 28407594
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways.
Wu KN; Zhao YM; He Y; Wang BS; Du KL; Fu S; Hu KM; Zhang LF; Liu LZ; Hu YX; Wang YJ; Huang H
Leuk Lymphoma; 2014 Mar; 55(3):668-76. PubMed ID: 23741975
[TBL] [Abstract][Full Text] [Related]
18. Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death.
Tosello V; Saccomani V; Yu J; Bordin F; Amadori A; Piovan E
Oncotarget; 2016 Jul; 7(29):45715-45729. PubMed ID: 27304189
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
[TBL] [Abstract][Full Text] [Related]
20. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
